Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and the Japanese Society of Clinical Cytology: An Extensive Study Containing More Benign Lesions

Akihiko Yoshizawa^a Kenzo Hiroshima^{b, c, d} Akemi Takenaka^e Reiji Haba^f
Kunimitsu Kawahara^g Yuko Minami^h Hirokuni Kakinumaⁱ Yasuo Shibuki^j
Shinji Miyake^k Kenta Kajio^g Kana Kiyonaga^f Moe Nagatomo^l
Sanako Nishimura^m Masayuki Mano^e Jun Matsubayashiⁿ Noriko Motoi^o
Toshitaka Nagaoⁿ Shin-ichi Nakatsuka^m Tsutomu Yoshida^p Yukitoshi Satoh^q

^aDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan; ^bDepartment of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan; ^cDepartment of Biochemistry and Genetics, Chiba University Graduate School of Medicine, Chiba, Japan; ^dSodegaura Satsukidai Hospital, Sodegaura, Japan; ^eDepartment of Central Laboratory and Surgical Pathology, National Hospital Organization Osaka National Hospital, Osaka, Japan; ^fDepartment of Diagnostic Pathology, Kagawa University Hospital, Kagawa, Japan; ^gDepartment of Pathology, Osaka Habikino Medical Center, Osaka, Japan; ^hDepartment of Diagnostic Pathology, National Hospital Organization Ibarakihigashi National Hospital, the Center of Chest Diseases and Severe Motor & Intellectual Disabilities, Ibaraki, Japan; ⁱDepartment of Pathology, Kumamoto University Hospital, Kumamoto, Japan; ^jDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan; ^kDepartment of Diagnostic Pathology, Tokyo Medical University Hospital, Tokyo, Japan; ^lDepartment of Central Laboratory, Osaka Toneyama Medical Center, Osaka, Japan; ^mDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan; ⁿDepartment of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan; ^oDepartment of Pathology, Saitama Cancer Center, Saitama, Japan; ^pDepartment of Pathology, Kitasato University School of Medicine, Sagami-hara, Japan; ^qDepartment of Thoracic Surgery, Kitasato University School of Medicine, Sagami-hara, Japan

Keywords

Cytology · Reporting system · Classification · Risk of malignancy · Pulmonary cytology

Abstract

Introduction: The Japan Lung Cancer Society (JLCS) and the Japanese Society of Clinical Cytology (JSCC) have proposed a new four-tiered cytology reporting system for lung carcinoma (JLCS-JSCC system). Prior to the proposal, the Papani-

colaou Society of Cytopathology (PSC) had proposed a revised reporting system (PSC system), which comprises the "neoplastic, benign neoplasm, and low-grade carcinoma" category (N-B-LG category), in addition to the 4 categories of the JLCS-JSCC system. This study aimed to evaluate the interobserver agreement of the JLCS-JSCC system with an additional dataset with more benign lesions in comparison with the PSC system. **Methods:** We analyzed 167 cytological samples, which included 17 benign lesions, obtained from the respiratory system. Seven observers classified these cas-

es into each category by reviewing one Papanicolaou-stained slide per case according to the J LCS-JSCC system and PSC system. **Results:** The interobserver agreement was moderate in the J LCS-JSCC ($k = 0.499$) and PSC ($k = 0.485$) systems. Of the 167 samples, 17 samples were benign lesions: 7 pulmonary hamartomas, 5 sclerosing pneumocytomas, 2 squamous papillomas, one solitary fibrous tumor, one meningioma, and one lymphocytic proliferation. There were diverse sample types as follows: 11 touch smears, 3 brushing smears, 2 aspirations, and one sputum sample. Fourteen samples (82.3%) were categorized into “negative” or “atypical” by more than half of the observers in the J LCS-JSCC system. Conversely, 3 samples were categorized as “suspicious” or “malignant” by more than half of the observers in the J LCS-JSCC system. On the other hand, 11 samples (64.7%) were categorized into the N-B-LG category by more than half of the observers in the PSC system. **Conclusions:** The concordance rate in the J LCS-JSCC system was slightly higher than that in the PSC system; however, the interobserver agreement was moderate in both the J LCS-JSCC and PSC systems. These results indicate that both the J LCS-JSCC and PSC systems are clinically useful. Therefore, both systems are expected to have clinical applications. It may be important to integrate the 2 systems and construct a universal system that can be used more widely in clinical practice.

© 2021 The Author(s).
Published by S. Karger AG, Basel

Introduction

Lung cancer is the leading cause of cancer-related deaths worldwide [1, 2]. Pathological and cytological classifications of lung carcinoma are crucial for effective patient management [3]. With the possibility of long-term survival through personalized medicine, cytology is becoming increasingly important, and there is a need for the standardization of guidelines in the field of cytology. However, no widely accepted categorization system for respiratory cytology has been established to date. In 2016, the Papanicolaou Society of Cytopathology (PSC) proposed a pulmonary cytology specimen terminology and revised a classification (PSC system) [4, 5]; it comprises the following 6 categories: “nondiagnostic,” “negative for malignancy,” “atypical,” “neoplastic, benign neoplasm, and low-grade carcinoma,” “suspicious for malignancy,” and “positive for malignancy.” Conversely, the Japan Lung Cancer Society (JLCS) and Japanese Society of Clinical Cytology (JSCC) have proposed a new reporting system for lung carcinoma (J LCS-JSCC system) based on the results evaluated by 7 cytopathologists from multicenters

[6]. The J LCS-JSCC reporting system comprises 3 steps (Table 1). First, the samples are classified as adequate for diagnostic evaluation or inadequate, owing to processing and/or staining artifacts. Second, if the samples are adequate, they are classified into the following 4 categories: “negative for malignancy,” “atypical cells,” “suspicious for malignancy,” and “malignancy.” One of the differences between the PSC and J LCS-JSCC systems is regarding the categorization of benign lesions. Our previous study had included a few cases diagnosed as benign neoplasms [6]; in the present study, we collected additional cytological specimens, including more benign neoplasm cases, from multiple centers in the same manner. This study aimed to confirm the utility of the J LCS-JSCC system with an additional dataset with more benign lesions than in the PSC system.

Materials and Methods

Data Collection

Cytological samples were collected in the same manner as we did previously. Briefly, 167 cytological samples were collected, which were extended from the previous study, from 8 hospitals (Kagawa University Hospital, Osaka Habikino Medical Center, National Organization Hospital Ibarakihigashi National Hospital, Tokyo Medical University Hospital, Osaka International Cancer Institute, National Hospital Organization Osaka National Hospital, National Cancer Center Hospital, and Kitasato University Hospital). The hospitals randomly selected the cases with electronic medical records and collected one Pap-stained glass slide per patient. After excluding cases with an “inadequate” category to evaluate target cells on the provided glass slides, glass slides were sent to a management cytotechnologist (A.T.) with clinical information (age and sex), and the final clinicopathological diagnosis of each case was made at the hospitals. Subsequently, glass slides were randomized and anonymized by the management cytotechnologist and were sent to 7 institutes, including the 3 hospitals, without clinical information and final clinicopathological diagnosis.

Evaluation

Cytotechnologists and cytopathologists from the 7 hospitals classified the slides into each category by reviewing both the J LCS-JSCC system (four-tier method) and PSC system (five-tier method) [5, 6]. Briefly, the J LCS-JSCC system comprises the following categories: negative for malignancy (NM), atypical cells (ACs), suspicious for malignancy (SM), and malignancy (ML); the PSC system comprises the following categories: NM and AC; and the neoplastic, benign neoplasm, and the low-grade carcinoma (N-B-LG) category: SM and ML. The observers had 7–36 years of experience. They entirely evaluated the glass slides, although there were some markings by cytotechnologists on the glass slides. The evaluation was performed after a washout interval of at least over 2 months. After the evaluation, the data were sent for analysis. An agreement was regarded as unanimous if all the observers agreed,

Table 1. Categories and definitions of the JLCS-JSCC system*

Step	Diagnostic category	Definition
First step	Adequate	Adequate for cytological evaluation
	Inadequate	Inadequate for cytological evaluation
Second step (if adequate in the first step)	NM	The absence of malignancy and any significant cellular atypia
	ACs	Cytomorphological aberrations that are greater than those of the NM category but less than those assignable to the SM category
	SM	Cytomorphological features that are suspicious but not diagnostic of carcinomas due to insufficient features characteristic of carcinomas and/or an insufficient number of ACs to be diagnosed as ML
	ML	Cytomorphological features that are unequivocally malignant
Third step	(Pathological classification is made if possible)	

JSCC, Japan Lung Cancer Society; JLCS, Japanese Society of Clinical Cytology; NM, negative for malignancy; AC, atypical cells; SM, suspicious for malignancy; ML, malignancy. * The JLCS and JSCC cytology reporting system for lung carcinoma

sub-unanimous if 6 or 7 observers agreed, and consensus if 4 or more of the observers agreed. Risk of malignancy (ROM) was defined for each category as the number of confirmed malignant cases divided by the total number of cases in the diagnostic category of each observer, and the mean ROM among the observers was calculated.

Statistical Analyses

Fleiss kappa (κ) for overall agreement among all observers was calculated for pairwise comparison between individual observers [7]. The level of agreement based on the kappa statistics was defined as follows: $\kappa < 0.20$ as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as good, and >0.81 as very good agreement [8]. The kappa score was calculated using statistical software CRAN.R irr package (ver.4.1.0).

Results

Patients' Demographics

Patients' ages ranged from 29 to 88 years; 102 of them were men, and 65 were women. Most of the samples were obtained via bronchial brushing ($n = 72$, 43.1%), followed by touch smear ($n = 27$, 16.1%) and transbronchial aspiration cytology (TBAC) ($n = 20$, 12.0%). Additionally, samples from endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), sputum, bronchoalveolar lavage, transcutaneous aspiration cytology, and CT-guided needle cytology were also included (Table 2). The final clinicopathological diagnosis was made based on the pathological diagnosis at the hospitals. As biopsy could not be performed, some cases were diag-

Table 2. Patients' demographical data and type of cytological procedure

Type of procedure		N	%
Total		167	100
Age (range)		66.5 (29–88)	
Male/female		102/65	61.1/38.9
Methods	Brushing	72	43.1
	Touch	27	16.1
	TBAC	20	12
	EBUS-TBNA	18	10.7
	Sputum	16	9.6
	BAL	12	7.2
	Others*	2	1.2

TBAC, transbronchial aspiration cytology; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration. Others* contained transcutaneous aspiration cytology, CT-guided needle cytology.

nosed based only on cytology specimens or clinical findings (Table 3). The final clinicopathological diagnoses of the cases without malignancy at the hospitals were as follows: 17 benign tumors (10.2%), 15 negatives (9.0%), 13 nonspecific inflammation (7.8%), 8 granulomas (4.8%), 5 infections (3.0%), 3 interstitial pneumonia (1.8%), and 6 others (3.6%). Malignant tumors comprised 95 primary lung carcinomas and 5 others as follows: 50 adenocarcinomas (29.9%), 21 squamous-cell carcinomas (12.6%), 12

Fig. 1. Distribution of the number of concordant observers in the JSCC-JLCS system (a) and PSC system (b). c Consensus (blue box), sub-unanimous (green box), and unanimous (red box) agreements in each system are shown. JSCC-JLCS system, Japan Lung Cancer Society and Japanese Society of Clinical Cytology reporting system for lung carcinoma; PSC, Papanicolaou Society of Cytopathology reporting system for lung carcinoma.

Table 3. Detailed final diagnosis

Category		N	%
Benign	Negative	15	9
	Nonspecific inflammation	13	7.8
	Granuloma	8	4.8
	Infection	5	3
	Interstitial pneumonia	3	1.8
	Others*	6	3.6
Benign tumor/UM	(Detail in Table 4)	17	10.2
Malignant	Adenocarcinoma	50	29.9
	Squamous-cell carcinoma	21	12.6
	Small-cell carcinoma	12	7.2
	Carcinoid	4	2.4
	Carcinoma, not otherwise specified	4	2.4
	LCNEC	2	1.2
	Salivary gland carcinoma	2	1.2
	Lymphoma	2	1.2
	Metastatic lung tumor	3	1.8

UM, uncertain malignant; LCNEC, large-cell neuroendocrine carcinoma. Others* contained asthma, radiation pneumonia, eosinophilic pneumonia, atelectasis, and chronic obstructive pulmonary disease.

small-cell carcinomas (7.2%), 4 carcinoid tumors (2.4%), 4 not-otherwise-specified carcinomas (2.4%), 2 large-cell neuroendocrine carcinomas (1.2%), 2 salivary gland-type carcinomas (1.2%), 3 metastatic lung tumors (1.8%), and 2 lymphomas (1.2%).

Cytological Diagnosis Agreement among Seven Observers in the JLCS-JSCC and PSC Systems

The distribution of the number of concordant observers in the JLCS-JSCC and PSC systems is presented in Figure 1. The consensus agreement and unanimous agreement in the JLCS-JSCC system were 87.4% and 40.7%, respectively, whereas those in the PSC system were 85.6% and 35.3%, respectively. If the SM and ML categories were combined in each system, sub-unanimous agreement in the JLCS-JSCC and PSC systems was 60.4% and 52.7%, respectively.

Interobserver Agreement

The interobserver agreement was moderate in both reporting systems. However, the agreement was better for the JLCS-JSCC system with a kappa of 0.499 (range, 0.405–0.650) than for the PSC system with a kappa of 0.485 (range, 0.379–0.681).

Fig. 2. Cytological features of hamartomas (case 3). Typical images of hamartoma showing proliferation of single spindle-shaped cells intermingling with the cartilaginous matrix; intermediate magnification ($\times 200$; **a**) and higher magnification of **a** ($\times 400$; **b**).

Table 4. Final diagnoses of benign lesions

Case #	Final diagnosis	Specimen type	JLCS-JSCC system*				PSC system**				
			NM	AC	SM	ML	NM	AC	N-B-LG	SM	ML
1	Hamartoma	Touch	3	3	1	0	2	1	4	0	0
2	Hamartoma	Touch	7	0	0	0	2	0	5	0	0
3	Hamartoma	Touch	6	0	1	0	2	0	4	1	0
4	Hamartoma	Touch	7	0	0	0	3	0	4	0	0
5	Hamartoma	Touch	7	0	0	0	2	0	5	0	0
6	Hamartoma	Touch	7	0	0	0	4	0	3	0	0
7	Hamartoma	Brush	1	4	1	1	1	3	1	1	1
8	SP	Touch	2	1	0	4	0	0	4	0	3
9	SP	Touch	5	0	0	2	1	0	4	0	2
10	SP	Touch	4	2	0	1	1	0	5	0	1
11	SP	Aspiration	2	3	0	2	1	0	4	0	2
12	SP	Aspiration	3	3	0	1	2	1	3	0	1
13	PP	Brush	0	1	2	4	0	1	0	2	4
14	PP	Sputum	2	2	0	3	2	2	1	2	0
15	SFT	Touch	2	1	1	3	1	0	4	0	2
16	Meningioma	Touch	4	2	1	0	1	0	6	0	0
17	Lymphoid hyperplasia	Brush	6	1	0	0	6	1	0	0	0

NM, negative for malignancy; AC, atypical cells; N-B-LG, neoplastic, benign neoplasm, and low-grade carcinoma; SM, suspicious for malignancy; ML, malignancy; PSC, Papanicolaou Society of Cytopathology; JSCC, Japan Lung Cancer Society; JLCS, Japanese Society of Clinical Cytology; SFT, solitary fibrous tumor; PP, squamous papilloma; SP, sclerosing pneumocytoma. * The JLCS and JSCC cytology reporting system for lung carcinoma. ** The PSC reporting system for lung carcinoma.

Determination of Benign Lesions Using the JLCS-JSCC and PSC Systems

The cohort contained 17 benign tumor cases (10.1%). Hamartomas were the most common lesion (7/17, 41.1%), followed by sclerosing pneumocytoma (SP) (5/17, 29.4%)

and squamous papilloma (PP) (2/17, 11.8%), as well as one meningioma, one solitary fibrous tumor (SFT), and one lymphoid hyperplasia (Table 4). The most common procedure type was touch smear (11/17, 64.7%), and other procedure types included brushing, 3 cases; aspiration,

Fig. 3. Cytological features of SP (case 8). The intermediate magnification image (a) shows prominent papillary growth pattern along with vascular cores (arrow) ($\times 200$). The higher magnification image (b) shows differently sized cuboidal cells ($\times 400$). A higher magnification of the other area (c) shows hemosiderin-laden macrophages ($\times 400$). SP, sclerosing pneumocytoma.

Table 5. Tumors categorized as “benign neoplasm or low-grade carcinoma” in the PSC system* by each observer

Final diagnosis	Ob1	Ob2	Ob3	Ob4	Ob5	Ob6	Ob7
No ML	2	0	0	0	0	0	0
Benign tumor	12	2	8	14	9	1	13
ML	0	1	8	0	1	4	2
Total	14	3	16	14	10	5	15
Accuracy of diagnosis %**	85.7	66.7	50	100	90	20	88.2
Ratio of malignancy %***	0	33.3	50	0	10	80	13.3

Ob, observer; PSC, Papanicolaou Society of Cytopathology; ML, malignancy. *The PSC reporting system for lung carcinoma. ** Accuracy of diagnosis shows the proportion of cases that were benign tumors in each observer’s category of “benign neoplasm or low-grade carcinoma.” *** Ratio of malignancy shows the proportion of cases that were malignant in each observer’s category of “benign neoplasm or low-grade carcinoma.”

2; and sputum, one. In the JLCS-JSCC system, most cases (15/17, 88.2%) were of the benign category (NM or AC). A typical image of a hamartoma showing proliferation of single spindle-shaped cells intermingling with the cartilaginous matrix is presented in Figure 2 (case 3). Six cytotechnologists have determined this case to be in the benign category. Three cases, which more than half of the cytotechnologists determined as the SM or ML category, included SP (case 8), PP (case 13), and SFT (case 15). Figure 3 presents the cytological features of SP (case 8), showing a prominent papillary growth pattern (Fig. 3a) with differently sized cuboidal cells (Fig. 3b) admixed

with hemosiderin-laden macrophages (Fig. 3c). In some areas, a large nucleus or nuclear grooving was observed (Fig. 3b), and many observers in our study suspected pulmonary adenocarcinoma with these features. The cytological features of the SFT with a cellular area composed of oval to short spindle cells with scant cytoplasm are presented in Figure 4 (case 15). Since this case contained a cellular area with ACs, more than half of the observers suspected nonsmall-cell carcinoma with high-grade atypia. According to the PSC system, 11 cases (64.7%) were categorized as N-B-LG by more than half of the observers (Table 4). The details of each observer’s assessment of N-

Fig. 4. Cytological and histological features of an SFT (case 15). High-magnification images (**a**, **b**) show a cellular area composed of oval to short spindle-shaped cells with scant cytoplasm ($\times 400$). Hematoxylin-eosin staining (**c**) showed a patternless architecture with alternating hypo- and hypercellular areas and a prominent branching vasculature ($\times 100$). The higher magnification image of the hematoxylin-eosin staining (**d**) shows differently sized cuboidal to spindle-shaped cells within dense collagen ($\times 400$). SFT, solitary fibrous tumor.

B-LG category lesions according to the PSC system are presented in Table 5. There were cases wherein 5 of the 7 observers judged the lesion to be malignant, even though they should be in the benign category (average, 26.7%; range, 0–80%).

ROM, Sensitivity, and Specificity

The average ROM in the JLCS-JSCC system according to the 7 observers was 17.7% (13.6–27.5%) for the NM category, 42.8% (21.1–62.5%) for the AC category, 67.1% (50.0–80.0%) for the SM category, and 91.4% (80.9–96.8%) for the ML category (Table 6). It was clearly stratified from the NM category to the ML category, which was the same as our previous finding [6]. If the NM and AC categories and SM and ML categories in the JLCS-JSCC system were regarded as negative and positive re-

sults, respectively, the average sensitivity and specificity were 80.6% (range, 65.6–91.0%) and 80.7% (range, 67.0–89.0%), respectively. On the other hand, the average ROM in the PSC system according to the 7 observers was 20.0% (13.6–28.5%) for the NM category, 42.1% (23.5–77.2%) for the AC category, 31.7% (0–80.0%) for the N-B-LG category, 69.6% (59.1–80.0%) for the SM category, and 89.9% (70.4–98.1%) for the ML category.

Discussion

We demonstrated that the consensus and unanimous agreement of the JLCS-JSCC system were 87.4% and 40.7%, respectively, which were better than those in our prior study and those of the PSC system in our study. Fur-

Table 6. ROM of the JLCS-JSCC system* and PSC system**

Category	ROM of the JLCS-JSCC system in this study, %	ROM of the PSC system in this study, %	ROM of PSC guidelines, % [5]	ROM of the PSC system from a report by Canberk et al., % [9]
Nondiagnostic	NA	NA	40	64.01
NM	17.7 (13.6–27.5)	20.0 (13.6–28.5)	24–43	48.27
ACs	42.8 (21.1–62.5)	42.1 (23.5–77.2)	54	59.09
N-B-LG	–	31.7 (0–80.0)	NA	100
SM	67.1 (50.0–80.0)	69.6 (59.1–80.0)	82	90.00
ML	91.4 (80.9–96.8)	89.9 (70.4–98.1)	77–100	89.74

ROM, risk of malignancy; NA, not available; N-B-LG, neoplastic, benign neoplasm, and low-grade carcinoma; NM, negative for malignancy; AC, atypical cells; SM, suspicious for malignancy; ML, malignancy; PSC, Papanicolaou Society of Cytopathology; JSCC, Japan Lung Cancer Society; JLCS, Japanese Society of Clinical Cytology. * The JLCS and JSCC cytology reporting system for lung carcinoma. ** The PSC reporting system for lung carcinoma.

ther, the average ROM in the JLCS-JSCC system according to the 7 observers was clearly stratified from the NM category to the ML category, which was the same as our previous finding. For benign lesions, most cases (88.2%) were categorized as negative or atypical in the JLCS-JSCC system. Since our study was extended from our previous study with more benign tumors involved, our results may indicate that the JLCS-JSCC system is acceptable for clinical use.

Since a widely accepted classification scheme for respiratory cytology, which leads to good communication between physicians and cytopathologists, has not been established, the PSC has proposed a revision of the reporting system for pulmonary cytology based on multidisciplinary formulation consisting of pathologists, radiologists, oncologists, and surgeons in 2016 [5]. The categories include nondiagnostic, NM, AC, N-B-LG, SM, and ML. To clarify the utility of the system, some researchers have reported ML risk categories to set up rational patient management. In the report by Layfield et al. [5], ROMs were 20–43% for the NM category, 54% for AC, 82% for SM, and 77–100% for ML (Table 6). Canberk et al. [9] have calculated the ROM with 1,290 respiratory cytology samples, with 48.27% for the NM category, 59.09% for AC, 90% for SM, and 89.74% for ML. In our study, the average ROM in the PSC system according to the 7 observers was 20.0% for the NM category, 42.1% for the AC category, 69.6% for the SM category, and 89.9% for the ML category. On the other hand, the average ROM in the JLCS-JSCC system according to the 7 observers was 17.7% for the NM category, 42.8% for AC, 67.1% for SM, and 91.4% for ML. Although the definitions of NM, AC, SM, and ML in the JLCS-JSCC system were not the same

as those in the PSC system, similar results were obtained in both systems. These results indicate that the JLCS-JSCC system is efficient for clinical use and that the PSC system can also be used in clinical settings. Thus, both systems are expected to have clinical applications.

Despite the usefulness of the PSC system from the ROM point of view, one of the reasons why the PSC system is difficult to use in clinical practice is because of the “N-B-LG” category. In the PSC system, the benign neoplasm category includes the following lesions: pulmonary hamartomas, PPs, granular cell tumors, hemangiomas, and SPs [10]. Additionally, the “neoplasm-undetermined malignant potential” category includes the following lesions: epithelioid hemangioendotheliomas, clear cell tumors, SPs, meningiomas, Langerhans cell histiocytosis, SFTs, inflammatory myofibroblastic tumors, and myoepithelial neoplasms. However, the categorization of such benign lesions has not been sufficiently evaluated, including in our previous study. Therefore, we evaluated the utility of both systems using the new cohort containing more benign tumors. In this cohort, there were 17 cases of benign lesions: 7 pulmonary hamartomas, 5 PPs, 2 SPs, one SFT, one meningioma, and one lymphoid hyperplasia. SP is a rare benign tumor of the lung and histologically shows papillary, solid, angiomatoid, or sclerotic or combinations of these 4 basic patterns [3]. SP typically presents as single discrete coin lesions on imaging; therefore, it is easy to suspect SP clinically. However, in our study, one of the 5 SPs was diagnosed as a malignant tumor by more than half of the observers in the JLCS-JSCC system; this may be because of cellular ACs that were observed and that the diagnosis was made without clinical information, such as radiology findings. SP can be misdi-

agnosed as malignant if clinical information is not provided. Moreover, in this cohort, one SFT was included. An SFT is a mesenchymal tumor of the fibroblastic type that can affect virtually any region of the body [11]. Neoplastic cells were arranged in a patternless architecture with alternating hypo- and hypercellular areas and a prominent branching vasculature. Most tumors present as well-defined, slow-growing masses, which can be cured by surgery. In contrast, a small percentage of SFTs (10–25%) behaved in a more aggressive way, with local recurrence [3]. Determining the tumor if it is benign or malignant with cytology and biopsy specimens is difficult if the clinical information, such as age or tumor size, is lacking [3]. In our study, over half of the observers categorized this case as SM or ML. We consider that this decision was reasonable because an SFT is a very rare tumor, and the specimen showed a very cellular area composing of oval to short spindle-shaped cells with scant cytoplasm. Further, there were cases in which 5 of the 7 observers judged the lesion as malignant, although they should be in the benign category. Fundamentally, the purpose of cytology was not to accurately detect benign lesions but to prevent malignant lesions from being overlooked. Taken together, the N-B-LG category may not be appropriate for clinical practice. However, in the current study, the average ROM in the PSC system according to the 7 observers was 31.7% for the N-B-LG category, which was lower than the one for the AC category. This result may be significant for the establishment of the N-B-LG category; however, it may also be because data were obtained from observers with sufficient experience in this field. We believe that the classification scheme should be a universal system that can be used by both experienced and inexperienced cytopathologists worldwide. Therefore, further studies of the N-B-LG category are necessary.

Regarding the nonadequate category, previous studies have shown ROM of nonadequate cases. Layfield et al. [5] reported that the ROM of the category was 40% (Table 6). On the other hand, Canberk et al. [9] reported that the ROM of the category was 64.01% in their study of 1,290 respiratory cytology samples. In the JLCS-JSCC system, cases are classified into the nonadequate or adequate category at the first step [9]. Only adequate cases were included in this study; thus, data for the nonadequate cases are unavailable. Since the nonadequate cases have been shown to have a high ROM in previous studies, we intend to study the ROM in such cases in a future study.

The previous cohort included only 2 benign lesions, and thus, we collected more benign lesions in the pres-

ent study. However, our study still has some limitations. First, as mentioned in our previous study, since clinical information or imaging findings were not provided to the observers, the cytological diagnosis was made only based on Pap-stained slides. This method of cytological evaluation is different from that of cytological diagnosis in daily practice. If clinical information and imaging findings were provided to the observers, cytological agreement among the observers would improve. Second, samples were not consecutive and were selected by cytotechnologists or cytopathologists of the hospitals for the purpose of this interobserver reproducibility study. Especially, cases that involve difficulty in differentiation between benign and malignant lesions were included. This selection bias made cytological diagnosis more difficult than the routine cytological diagnosis in daily practice. Further studies on routine samples using the JLCS-JSCC system are needed to confirm our results. Third, TBACs or EBUS-TBNA, which are increasing in diagnostic practice, were limited in our study. In such cases, the determination of samples whether it is adequate or inadequate is more important than other types of specimens. In our study, inadequate cases were excluded. Further study with samples obtained using TBAC or EBUS-TBNA is needed to generalize our findings.

In conclusion, the JLCS-JSCC system is considered appropriate for clinical use, and the PSC system can also be used in clinical settings; thus, it is hard to consider one as more useful clinically than the other. Therefore, a unified system in the frame of the international activities such as the WHO is needed.

Acknowledgements

The authors thank Prof. Robert Y. Osamura, Prof. Fernando Schmitt, and Prof. Lukas Bubendorf for inspiring us to establish a new cytology reporting system for lung cancer. The authors also thank Dr. Satoru Shimizu for giving us advice on the statistical analyses of the data.

Statement of Ethics

Study approval statement: The study protocol was approved by the Ethics Committee of Tokyo Women's Medical University (approval number: 4873; approval date: July 26, 2018) and the Ethics Committee of all participating facilities. Consent was waived for this retrospective study which analyzed cytological specimens with limited clinical information.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

The JLCS and JSCC covered the expenses of the meeting, postal fee of the glass slides, and fee for the English editing service.

Author Contributions

Yoshizawa A., Hiroshima K., Takenaka A., Haba R., Kawahara K., Minami Y., Kakinuma H., Shibuki Y., Miyake S., and Satoh Y contributed to the study concept and design. Haba R., Kawahara K., Miyake S., Kajio K., Kiyonaga K., Matsubayashi J., and Nagao

T. provided glass slides. Takenaka A. collected and managed glass slides. Takenaka A., Haba R., Kawahara K., Kakinuma H., Shibuki Y., Miyake S., Kajio K., Kiyonaga K., Nagatomo M., Nishimura S., Mano M., Matsubayashi J., Motoi N., Nagao T., Nakatsuka S., and Yoshida T. reviewed the glass slides. Yoshizawa A., Hiroshima K., and Satoh Y. contributed to analysis and interpretation of data. Yoshizawa A. drafted the manuscript. Hiroshima K., Haba R., Kawahara K., Minami Y., and Satoh Y. contributed to critical revision of the manuscript.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

References

- 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(1):7–34.
- 2 Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. *Global Cancer Observatory: Cancer Today*. Lyon (France): International Agency for Research on Cancer; 2021 [cited 2021 June 06]. Available from: <https://gco.iarc.fr/today>.
- 3 WHO Classification of Tumours Editorial Board. *Thoracic Tumours. WHO Classification of Tumours*. 5th ed. Lyon (France): International Agency for Research on Cancer; 2021.
- 4 Guidelines of the papanicolaou society of cytopathology for the examination of cytologic specimens obtained from the respiratory tract. Papanicolaou society of cytopathology task force on standards of practice. *Diagn Cytopathol*. 1999;21(1):61–9.
- 5 Layfield LJ, Baloch Z, Elsheikh T, Litzky L, Rekhman N, Rektman N, et al. Standardized terminology and nomenclature for respiratory cytology: the papanicolaou Society of Cytopathology guidelines. *Diagn Cytopathol*. 2016;44(5):399–409.
- 6 Hiroshima K, Yoshizawa A, Takenaka A, Haba R, Kawahara K, Minami Y, et al. Cytology reporting system for lung cancer from the Japan Lung Cancer Society and Japanese Society of Clinical Cytology: an interobserver reproducibility study and risk of malignancy evaluation on cytology specimens. *Acta Cytol*. 2020;64(5):452–62.
- 7 Fleiss J, Levin B, Paik MC. *Statistical methods for rates and proportions*. 3rd ed. Hoboken, New Jersey: Wiley; 2003.
- 8 Ginter PS, Idress R, D'Alfonso TM, Fineberg S, Jaffer S, Sattar AK, et al. Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy. *Mod Pathol*. 2021;34(4):701–9.
- 9 Canberk S, Montezuma D, Aydın O, Demirhas MP, Denizci B, Akbas M, et al. The new guidelines of Papanicolaou Society of Cytopathology for respiratory specimens: assessment of risk of malignancy and diagnostic yield in different cytological modalities. *Diagn Cytopathol*. 2018;46(9):725–9.
- 10 Layfield LJ, Baloch Z. *The Papanicolaou society of cytopathology system for reporting respiratory cytology: definitions, criteria, explanatory notes, and recommendations for ancillary testing*. Switzerland: Springer Nature; 2019.
- 11 WHO Classification of Tumours Editorial Board. *Soft tissue and bone tumours. WHO Classification of Tumours*. 5th ed. Lyon (France): International Agency for Research on Cancer; 2020.